Company intelligence / Profile preview
Liminatus Pharma
Wilmington, Delaware, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Liminatus Pharma is a clinical-stage immuno-oncology company. Its lead asset is a guanylyl cyclase C (GCC) cancer vaccine in Phase 2 trials for metastatic colorectal, pancreatic, esophageal, and gastric cancers that express GCC.[4][6][7] The company is also preparing a GCC CAR-T program for first-in-human studies and advancing a next-generation CD47 immune checkpoint inhibitor, IBA101, through IND-enabling studies.[3][4][6]
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyVaccineMonoclonal antibodyAntibodyBiologicCell therapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Iris Acquisition Corp (business combination / SPAC transaction to form Liminatus Pharma, Inc.)[4][6]Thomas Jefferson University (origin of GCC vaccine and GCC CAR-T programs)[4][6]InnobationBio (origin of CD47 immune checkpoint inhibitor program)[4][6]GenScript ProBio (CMC and antibody development services for the CD47 program)[4][6]
Beyond the preview
Go deeper on Liminatus Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liminatus Pharma.